Experimental radioimmunotherapy

Medical Physics

Volumn 20, Issue 2, 1993, Pages 551-567

  Donald, J Buchsbaum ^a   Lanamuir, Virainia K ^b   Wessels, Barry W ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SRI INTERNATIONAL   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 212; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM 186; SAMARIUM 153; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY LABELING; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; EXPERIMENTAL NEOPLASM; HUMAN; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THERMOLUMINESCENCE DOSIMETRY; TUMOR SPHEROID; TUMOR XENOGRAFT;

ANIMAL; HAMSTERS; HUMAN; IN VITRO; MICE; MODELS, BIOLOGICAL; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; RATS; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0027284849     PISSN: 00942405     EISSN: NA     Source Type: Journal    
DOI: 10.1118/1.597142     Document Type: Article

References (125)

1. B. W. Wessels, “Current status of animal radioimmunotherapy,” Cancer Res. (Suppl.) 50, 970s-973s (1990).
2. L. F. Mausner and S. C. Srivastava, “Selection of radionuclides for radioimmunotherapy,” Med. Phys. 20, 503–509 (1993).
3. L. T. Dillman and F. C. Von der Lage, “Radionuclide decay schemes and nuclear parameters for use in radiationdose estimation,” in Medical Internal Radiation Dose (MIRD)(Society of Nuclear Medicine, New York, NY, 1975) Pamphlet No. 10, pp. 5–119.
4. M. J. Berger, “Biodistribution of absorbed dose around point sources of electrons and beta particles in water and other media,” MIRD Pamphlet No. 7, J. Nucl. Med. (Suppl.) 12 (5), 1–23 (1971).
5. V. K. Langmuir, J. F. Fowler, S. J. Knox, B. W. Wessels, R. M. Sutherland, and J. Y. C. Wong, “Radiobiology and radiolabeled antibody therapy as applied to tumor dosimetry,” Med. Phys. 20, 601–610 (1993).
6. R. Sutherland F. Buchegger, M. Schreyer, A. Vacca, and J. -P. Mach, “Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids,” Cancer Res. 47, 1627–1633 (1987).
7. K. A. Walker, T. Murray, T. E. Hilditch, T. E. Wheldon, A. Gregor, and I. M. Hann, “A tumour spheroid model for antibody-targeted therapy of micrometastases,” Br. J. Cancer 58, 13–16 (1988).
8. C. S. Kwok, S. E. Cole, and S. -K. Liao, “Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids,” Cancer Res. 48, 1856–1863 (1988).
9. C. S. Kwok, A. Crivici, W. D. MacGregor, and M. W. Unger, “Opti-mization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model,” Cancer Res. 49, 3276–3281 (1989).
10. V. K. Langmuir, J. K. McGann, F. Buchegger, and R. M. Sutherland “131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids,” Cancer Res. 49, 3401–3406 (1989).
11. V. K. Langmuir, R. W. Atcher, J. J. Hines, and M. W. Brechbiel, “Iodine-125-NRLU-10 kinetic studies and bismuth-212-NRLU-10 toxicity in LS174T multicell spheroids,” J. Nucl. Med. 31, 1527–1533 (1990).
12. V. K. Langmuir, J. K. McGann, F. Buchegger, and R. M. Sutherland, “The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids,” Nucl. Med. Biol. 18, 753–764 (1991).
13. V. K. Langmuir, H. L. Mendonca, and D. V. Woo, “Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: Uptake kinetics and l25I-antibody efficacy in multicell spheroids,” Cancer Res. 52, 4728–4734 (1992).
14. V. K. Langmuir, H. L. Mendonca, J. -L. Vanderheyden, and F. -M. Su, “Comparisons of the efficacy of 186Re- and 131I-labeled antibody in multicell spheroids,” Int. J. Radiat. Oncol. Biol. Phys. 24, 127–132 (1992).
15. V. K. Langmuir and H. L. Mendonca, “The role of radionuclide distribution in the efficacy of 131I-labeled antibody as modeled in multicell spheroids,” Antib. Immunoconj. Radiopharm. 5, 273–283 (1992).
16. V. K. Langmuir and R. M. Sutherland“Dosimetry models for radioimmunotherapy,” Med. Phys. 15, 867–873 (1988).
17. M. Bardies, J. Lame, M. J. Myers, and J. P. Simoen, “A simplified approach to beta dosimetry for small spheres labelled on the surface,” Phys. Med. Biol. 35, 1038–1050 (1990).
18. M. Bardies, P. Thedrez, J. F. Gestin, and M. B. Marcille, “Use of multicell spheroids of ovarian carcinoma as an intraperitoneal radioimmunotherapy model: Uptake, retention kinetics and dosimetric evaluation,” Int. J. Cancer 50, 984–991 (1992).
19. V. K. Langmuir, B. W. Wessels, H. L. Mendonca, E. D. Yorke, and L. Montilla, “Comparisons of sectioned micro-TLD dose measurements with predicted dose from niI-labeled antibody,” Med. Phys. 19, 1213–1218 (1992).
20. D. M. Goldenberg, S. A. Gaffar, S. J. Bennett, and J. L. Beach, “Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen,” Cancer Res.,41 4354—4360 (1981).
21. R. M. Sharkey, M. J. Pykett, J. A. Siegel, E. A. Alger, F. J. Primus, and D. M. Goldenberg, “Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen,” Cancer Res. 47, 5672–5677 (1987).
22. J. M. Esteban, J. Schlom, F. Momex, and D. Colcher, “Radio-immunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs,” Eur. J. Cancer Clin. Oncol. 23, 643–655 (1987).
23. J. R. Zalcberg, C. H. Thompson, M. Lichtenstein, and I. F. C. McKenzie, “Tumor immunotherapy in the mouse with the use of l3, I-labeled monoclonal antibodies,” J. Natl. Cancer Inst. 72 697–704 (1984).
24. B. W. Wessels, M. H. Griffith, E. W. Bradley, and B. Sibinski, “Dosimetric measurements and radiobiological consequences of radioimmunotherapy in tumor bearing mice,” in Fourth International Radiopharmaceutical Dosimetry Symposium, edited by A. T. Schlafke-Stelson and E. E. Watson (Oak Ridge Associated Universities, Oak Ridge, TN), 1968 446–457.
25. B. W. Wessels, R. L. Vessella, D. F. Palme II, J. M. Berkopec, G. K. Smith, and E. W. Bradley, “Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts,” Int. J. Radiat. Oncol. Biol. Phys. 17, 1257–1263 (1989).
26. D. J. Buchsbaum, R. K. Ten Haken, D. B. Heidom, T. S. Lawrence A. A. Glatfelter, V. H. Terry, D. M. Guilbault, Z. Steplewski, and A. S. Lichter, “A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts,” Int. J. Radiat. Oncol. Biol. Phys. 18, 1033–1041 (1990).
27. D. J. Buchsbaum, P. G. Brubaker, D. E. Hanna, A. A. Glatfelter, V. H. Terry, D. M. Guilbault, and Z. Steplewski, “Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies,” Cancer Res. (Suppl.) 50, 993s-999s (1990).
28. W. P. Neacy, B. W. Wessels, E. W. Bradley, S. Kovandi, T. Justice, S. Danskin, and H. Sands, “Comparison of radioimmunotherapy (RIT) and 4 MV external beam radiotherapy of human tumor xenografts in athymic mice,” J. Nucl. Med. 27, 902–903 (1986).
29. M. H. Griffith, E. D. Yorke, B. W. Wessels, G. L. DeNardo, and W. P. Neacy, “Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy,” J. Nucl. Med. 29, 1795–1809 (1988).
30. P. L. Roberson, D. J. Buchsbaum, D. B. Heidom, and R. K. Ten Haken, “Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography,” Int. J. Radiat. Oncol. Biol. Phys. 24, 329–334 (1992).
31. P. L. Roberson, D. J. Buchsbaum, D. B. Heidom, and R. K. Ten Haken, “Variations in 3-D dose distributions for 131 Iodine-labeled monoclonal antibody,” Antib- Immunoconj. Radiopharm. 5, 397–402 (1992).
32. F. Buchegger, A. Pelegrin, B. Delaloye, A. Bischof-Delaloye, and J. -P. Mach, “Iodine-131-labeled MAb F(ab‘)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice,” J. Nucl. Med. 31, 1035–1044 (1990).
33. F. Buchegger, C. Pfister, K. Fournier, F. Prevel, M. Schreyer, S. Carrel, and J. -P. Mach, “Ablation of human colon carcinoma in nude mice by 13lI-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab‘)2 fragments,” J. Clin. Invest. 83, 1449–1456 (1989).
34. F. Buchegger, A. Vacca, S. Carrel, M. Schreyer, and J. -P. Mach, “Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model,” Int. J. Cancer 41, 127–134 (1988).
35. R. M. Sharkey, K. S. Weadock, A. Natale, L. Haywood, R. Aninipot, R. D. Blumenthal, and D. M. Goldenberg, “Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice,” J. Natl. Cancer Inst. 83 627–632 (1991).
36. T. Yokota, D. E. Milencic, M. Whitlow, and J. Schlom, “Rapid tumor penetration of a single-chain Fv and comparison with other immunoforms,” Cancer Res. 52, 3402–3408 (1992).
37. J. Schlom, A. Molinolo, J. F. Simpson, K. Siler, M. Roselli, G. Hinkle, D. P. Houchens, and D. Colcher, “Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy,” J. Natl. Cancer Inst. 82 763–771 (1990).
38. Y. C. Lee, L. C. Washburn, T. T. H. Sun, B. L. Byrd, J. E. Crook, and Z. Steplewski, “Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO 17-1A prepared by two bifunctional chelate techniques,” Cancer Res. 50, 4546–4551 (1990).
39. L. C. Washburn, T. T. H. Sun, Y. -C. C. Lee, B. L. Byrd, E. C. Holloway, J. E. Crook, J. B. Stubbs, M.G. Stabin, M. W. Brechbiel, O. A. Gansow, and Z. Steplewski, “Comparison of five bifunctional chelate techniques for labeled monoclonal antibody CO 17–1 A,” Nucl. Med. Biol. 18, 313–321 (1991).
40. L. C. Washburn, Y. -C. C. Lee, T. T. H. Sun, B. L. Byrd, E. C. Holloway, J. E. Crook, and Z. Steplewski, “Radioimmunotherapy of SW 948 human colorectal carcinoma xenografts with repeated injections of90Y-labeled monoclonal antibody CO 17–1 A.” Antib. Immunoconjug. and Radiopharm. 4, 729–734 (1991).
41. R. M. Sharkey, F. A. Kaltovich, L. B. Shih, I. Fand, G. Govelitz, and D. M. Goldenberg, “Radioimmunotherapy of human colonic cancer xenografts with90Y-labeled monoclonal antibodies to carcinoembryonic antigen,” Cancer Res. 48, 3270–3275 (1988).
42. R. R. Buras, B. G. Beatty, L. E. Williams, P. M. Wanek, J. B. Harris, R. Hill, and J. D. Beatty, “Radioimmunotherapy of human colon cancer in nude mice,” Arch. Surg. 125, 660–664 (1990).
43. R. R. Buras, J. Y. C. Wong, J. A. Kuhn, B. G. Beatty, L. E. Williams, P. M. Wanek, and J. D. Beatty, “Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer xenografts,” Int. J. Radiat. Oncol. Biol. Phys. 25, 473–479 (1993).
44. J. A. Kuhn, B. G. Beatty, J. Y. C. Wong, J. M. Esteban, P. M. Wanek, F. Wall, R. R. Buras, L. E. Williams, and J. D. Beatty, “Interferon enhancement of radioimmunotherapy for colon carcinoma,” Cancer Res. 51, 2335–2339 (1991).
45. C. S. Heacock, A. M. Blake, C. J. D'Aleo, and V. L. Alvarez, “Use of an yttrium-90 labeled antibody for the treatment of human colon cancer xenografts in nude mice,” Synthesis and Applications of Isotopically Labelled Compounds, 783–786 (1989).
46. D. J. Buchsbaum, T. S. Lawrence, P. L. Roberson, D. B. Heidom, R. K. Ten Haken, and Z. Steplewski, “Comparison of 131I- and labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts,” Int. J. Radiat. Oncol. Biol. Phys. 25, 629–638 (1993).
47. R. M. Sharkey, C. Motta-Hennessy, D. Pawlyk, J. A. Siegel, and D. M. Goldenberg, “Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts,” Cancer Res. 50, 2330–2336 (1990).
48. B. A. Morton, B. G. Beatty, A. Mison, P. M. Wanek, and J. D. Beatty, “Role of bone marrow transplantation in yttrium-90 antibody therapy of colon cancer xenografts in nude mice,” Cancer Res. (Suppl.) 50, 1008s-1010s (1990).
49. F. M. Uckun, L. Souza, K. G. Waddick, M. Wick, and C. W. Song, “In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice,” Blood 75, 638–645 (1990).
50. R. D. Blumenthal, R. M. Sharkey, D. J. Snyder, H. J. Hansen, and D. M. Goldenberg, “Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1,” Cancer Res. 48, 5403–5406 (1988).
51. F. M. Uckun, S. Gillis, L. Souza, and C. W. Song, “Effects of recombinant growth factors on radiation survival of human bone marrow progenitor cells,” Int. J. Radiat. Oncol. Biol. Phys. 16, 415–435 (1989).
52. V. S. Gallicchio, B. C. Hulette, M. J. Messino, C. Gass, M. W. Bie-schke, and M. A. Doukas, “Effect of various interleukins (IL-1, IL-2, and IL-3) on the in vitro radioprotection of bone marrow progenitors (CFU-GM and CFU-MEG),” J. Biol. Response Mod. 8, 479-487(1989).
53. R. Neta, S. Douches, and J. J. Oppenheim, “Interleukin 1 is a radio-protector,” J. Immunol. 136, 2483-2485 (1986).
54. R. Neta, J. J. Oppenheim, and S. D. Douches, “Interdependence of the radioprotective effects of human recombinant interleukin-1, tumor necrosis factor, granulocyte colony-stimulating factor and murine recombinant granulocyte-macrophage colony stimulating factor,” J. Immunol. 140, 108-111 (1988).
55. R. Neta, S. D. Douches, and J. J. Oppenheim, “Radioprotection by interleukin-1,” in UCLA Symposia on Molecular and Cellular Biology, edited by O. Goldstein, J. F. Bach, and H. Wigzal (Liss, New York, NY, 1986), p. 429.
56. R. Neta, J. I. Oppenheim, S. D. Douches, P. C. Giclas, R. J. Imbra, and M. Karin, “Radioprotection with interleukin-1: Comparison with other cytokines,” in Progress in Immunology, edited by B. Cinader and R. G. Miller (Academic, San Diego, CA, 1986), Vol. 6, pp. 900-908
57. R. Neta and J. J. Oppenheim, “Cytokines in therapy of radiation in-jury,” Blood 72, 1093-1095 (1988).
58. R. Neta, M. B. Sztein, J. J. Oppenheim, S. Gills, and S. D. Douches, “The in vivo effects of interleukin 1.1. Bone marrow cells are induced to cycle after administration of interleukin 1,” J. Immunol. 139, 1861-1866 (1987).
59. R. B. Pedley, R. H. J. Begent, J. A. Boden, R. Boden, T. Adam, and K.D. Bagshawe, “The effect of radiosensitizers on radioimmunotherapy, using mI-labelled anti-CEA antibodies in a human colonic xenograft model,” Int. J. Cancer 47, 597-602 (1991).
60. V. K. Langmuir and H. L. Mendonca, “The combined use of l3lI-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo,” Radiat. Res. 132, 351-358 (1992).
61. E. P. Malaise, B. Fertil, N. Chavaudra, and M. Guichard, “Distribution of radiation sensitivities for human tumor cells of specific histo-logical types: Comparison of in vitro to in vivo data,” Int. J. Radiat. Oncol. Biol. Phys. 12, 617-624 (1986).
62. W. R. Redwood, T. D. Tom, and M. Strand, “Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice,” Cancer Res. 44, 5681-5687 (1984).
63. W. T. Anderson-Berg, R. A. Squire, and M. Strand, “Specific radio-immunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice,” Cancer Res. 47, 1905-1912 (1987).
64. O. A. Gansow, M. W. Brechbiel, G. Pippin, R. Huneke, P. Squire, and M. Strand, “Synthesis of 2-(p-SCN-benzyl)-trans-cyclohexyl-DTPA (CHX-DTPA); Use for a-particle radioimmunotherapy with Bi-212-mAb-103A in mice infected with the Rauscher leukemia virus,” J. Nucl. Med. (Suppl.) 32, 1056 (1991).
65. R. M. Macklis, B. M. Kinsey, A. I. Kassis, J. L. M. Ferrara, R. W. Atcher, J. J. Hines, C. N. Coleman, S. J. Adelstein, and S. J. Burakoff, “Radioimmunotherapy with alpha-particle-emitting immunoconju-gates,” Science 240, 1024-1026 (1988).
66. R. M. Macklis, W. D. Kaplan, J. L. M. Ferrara, R. W. Atcher, J. J. Hines, S. J. Burakoff, and C. N. Coleman, “Residents essay award: Alpha particle radio-immunotherapy: Animal models and clinical prospects,” Int. J. Radiat. Oncol. Biol. Phys. 16, 1377-1387 (1989).
67. C. C. Badger, K. A. Krohn, A. V. Peterson, H. Shulman, and I. D. Bernstein, “Experimental radiotherapy of murine lymphoma with 13, I-labeled anti-Thy 1.1 monoclonal antibody,” Cancer Res. 45, 1536-1544 (1985).
68. C. Nourigat, C. C. Badger, and I. D. Bernstein, “Treatment of lym-phoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen,” J. Natl. Cancer Inst. 82, 47-50 (1990).
69. D. A. Adams, G. L. DeNardo, S. J. DeNardo, G. B. Matson, A. L. Epstein, and E. M. Bradbury, “Radioimmunotherapy of human lym-phoma in thymic, nude mice as monitored by 3, P nuclear magnetic resonance,” Biochem. Biophys. Res. Commun. 131, 1020-1027 (1985).
70. H. Schmidberger, D. J. Buchsbaum, B. R. Blazar, P. Everson, and D.A. Vallera, “Radiotherapy in mice with yttrium-90-labeled anti-Lylmonoclonal antibody: Therapy of the T cell lymphoma EL4,” Cancer Res. 51, 1883-1890 (1991).
71. R. A. Rostock, J. L. Klein, P. Leichner, K. A. Kopher, and S. E. Order, “Selective tumor localization in experimental hepatoma by ra-diolabeled antiferritin antibody,” Int. J. Radiat. Oncol. Biol. Phys. 9, 1345-1350 (1983).
72. J. L. Klein, T. H. Nguyen, P. Laroque, K. A. Kopher, J. R. Williams, B. W. Wessels, L. E. Dillehay, J. Frincke, S. E. Order, and P. K. Leichner, “Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma,” Cancer Res. 49, 6383–6389 (1989).
73. R. L. Vessella, V. Alvarez, R. -K. Chiou, J. Rodwell, M. Elson, D. Palme, R. Shafer, and a, “Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts,” Natl. Cancer Inst. Monogr. 3, 159–167 (1987).
74. R. K. Chiou, R. L. Vessella, C. Limas, R. B. Shafer, M. K. Elson, E. W. Arfman, and P. H. Lange, “Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse model,” Cancer 61, 1766–1775 (1988).
75. R. L. Vessella, P. H. Lange, D. F. Palme II, R. K. Chiou M. K. Elson, and B. W. Wessels, “Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice,” in Targeted Diagnosis and Therapy, edited by J. D. Rodwell (Marcel Dekker, New York, NY, 1988), Vol. I, pp. 245–282.
76. J. T. Kemshead, D. H. Jones, L. Lashford, J. Prichard, I. Gordon, F. Breatnach, and H. B. Coakham, “131-1 coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumors: Fact or fiction?” Cancer Drug Delivery 3, 25–43 (1986).
77. N.-K. Cheung, B. Landmeier, J. Neely, A. D. Nelson, C. Abramowsky, S. Ellery, R.B. Adams, and F. Miraldi, “Complete tumor ablation with iodine-131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice,” J. Natl. Cancer Inst. 77 739–745 (1986).
78. Y. -S. Lee, D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wik-strand, H. S. Friedman, E. V. Colapinto, and D. D. Bigner, “Thera-peutic efficacy of antiglioma mesenchymal extracellular matrix 13lI-radiolabeled murine monoclonal antibody in a human glioma xenograft model,” Cancer Res. 48, 559–566 (1988).
79. Y. Lee, D. E. Bullard, P. A. Humphrey, E. V. Colapinto, H. S. Friedman, M. R. Zalutsky, R. E. Coleman, and D. D. Bigner, “Treatment of intracranial human glioma xenografts with i31I-labeled anti-tenascin monoclonal antibody 81C6,” Cancer Res. 48, 2904–2910 (1988).
80. J. M. Schuster, P. K. Garg, D. D. Bigner, and M. R. Zalutsky, “Im-proved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl) benzoate,” Cancer Res. 51, 4164—4169 (1991).
81. M. R. Zalutsky, M. A., Noska, E. V. Colapinto E. Fuchs, and D. D. Bigner, “Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using Y-succinimidyl 3-(tri-«-butylstannyl) benzoate,” Cancer Res. 49, 5543–5549 (1989).
82. E. V. Colapinto, M. R. Zalutsky, G. E. Archer, M. A. Noska, H. S. Friedman, S. Carrel, and D. D. Bigner, “Radioimmunotherapy of intracerebral human glioma xenografts with 13JI-labeled F(ab‘)2 fragments of monoclonal antibody Mel-14,” Cancer Res. 50, 1822–1827 (1990).
83. J. A. Williams, B. W. Wessels, M. D. Wharam, S. E. Order, P. M. Wanek, J. K. Poggenburg, and J. L. Klein, “Targeting of human glioma xenografts in vivo utilizing radiolabeled antibodies,” Int. J. Radiat. Oncol. Biol. Phys. 18, 1367–1375 (1990).
84. M. R. Zalutsky, P. K. Garg, J. M. Schuster, S. Garg, G. E. Archer, H. E. Fuchs, and D. D. Bigner, “Effective treatment of experimental human neoplastic meningitis (NM) with intrathecal astatine-211 monoclonal antibody (MAb),” J. Nucl. Med. (Suppl.) 32, 922 (1991).
85. H. Bender, H. Takahashi, K. Adachi, P. Belser, S. Liang, M. Prewett, M. Schrappe, A. Sutter, U. Rodeck, and D. Herlyn, “Immunotherapy of human glioma xenografts with unlabeled, 13JI-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor,” Cancer Res. 52, 121–126 (1992).
86. J. L. Humm, J. C. Roeske, D. R. Fisher, and G. T. Y. Chen, “Micro-dosimetric concepts in radioimmunotherapy,” Med. Phys. 20, 535–544 (1993).
87. R. L. Ceriani and E. W. Blank, “Experimental therapy of human breast tumors with 13 labeled monoclonal antibodies prepared against the human milk fat globule,” Cancer Res. 48, 4664—4672 (1988).
88. R. L. Ceriani, E. W. Blank, J. A. Peterson, H. Battifora, and H. Singh, “Immunotherapeutic preclinical evaluation of anti-human milk fat globule MoAbs Mc5 and BrE-1,” Antib. Immunoconj. Radiopharm. 3, 181–198 (1990).
89. R. Senekowitsch, G. Reidel, S. Mollenstadt, H. Kriegel, and H. -W. Pabst, “Curative radioimmunotherapy of human mammary carcinoma xenografts with iodine-131-labeled monoclonal antibodies,” J. Nucl. Med. 30, 531-537 (1989).
90. S. Yoneda, M. Fujisawa, J. Watanabe, T. Okabe, F. Takaku, T. Homma, and K. Yoshida, “Radioimmunotherapy of transplanted small cell lung cancer with l5, I-labelled monoclonal antibody,” Br. J. Cancer 58, 292-295 (1988).
91. P. L. Beaumier, P. Venkatesan, J. -L. Vanderheyden, W. D. Burgua, L.L. Kunz, A.R. Fritzberg, P. G. Abrams, and A. C. Morgan, Jr., “186 Reradioimmunotherapy of small cell lung carcinoma xenografts in nude mice,” Cancer Res. 51, 676-681 (1991).
92. F. -M. Chen, D. K. Taylor, and A. L. Epstein, “Tumor necrosis treatment of ME-180 human cervical carcinoma model with l5lI-labeled TNTT-1 monoclonal antibody,” Cancer Res. 49, 4578-4585 (1989).
93. C. F. M. Molthoff, H. M. Pinedo, H. M. M. Schluper, and E. Boven, “Influence of dose and schedule on the therapeutic efficacy of l3lI-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model,” Int. J. Cancer 50, 474-480 (1992).
94. D. V. Lightfoot, K. K. Walker, G. R. Boniface, E. L. Hetherington, M.E. Izard, and P. J. Russell, “Dosimetric and therapeutic studies in nude mice xenograft models with l5Jsamarium-labelIed monoclonal anti-body, BLCA-38,” Antib. Immunoconj. Radiopharm. 4, 319-330(1991).
95. J. Schlom, K. Siler, D. E. Milenic, D. Eggensperger, D. Colcher, L. S. Miller, D. Houchens, R. Cheng, D. Kaplan, and W. Goeckeler, “Monoclonal antibody-based therapy of a human tumor xenograft with a l77Lutetium-labeled immunoconjugate,” Cancer Res. 51, 2889-2896(1991).
96. D. J. Buchsbaum, “Experimental radioimmunotherapy: Methods to increase therapeutic efficacy relevant to the study of human cancer,” Antib. Immunoconj. Radiopharm. 4, 693-701 (1991).
97. D. J. Buchsbaum and T. S. Lawrence, “Tumor therapy with radiolabeled monoclonal antibodies,” Antib. Immunoconj. Radio-pharm. 4, 245-272 (1991).
98. T. A. Waldmann, “Monoclonal antibodies in diagnosis and therapy,”Science 252, 1657-1662 (1991).
99. D. M. Goldenberg, R. D. Blumenthal, and R. M. Sharkey, “Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies,” Sem. Cancer Biol. 1, 217-225 (1990).
100. K. Yokoyama, J. C. Reynolds, C. H. Paik, V. K. Sood, P. J. Maloney, S. M. Larson, and R. C. Reba, “Immunoreactivity affects the biodis-tribution and tumor targeting of radiolabeled anti-P97 Fab fragment,”J. Nucl. Med. 31, 202-210 (1990).
101. M. Koizumi, K. Endo, Y. Watanabe, T. Saga, H. Sakahara, J. Konishi, T. Yamamuro, and S. Toyama, “Pharmocokinetics of internally labeled monoclonal antibodies as a gold standard: Comparison of biodistribution of 7Se-, 111mIn-, and l25I-labeled monoclonal antibodies in osteo-genic sarcoma xenografts in nude mice,” Cancer Res. 49, 1752-1757 (1989).
102. H. Sakahara, K. Endo, T. Nakashima, M. Koizumi, H. Ohta, K. Tor-izuka, T. Furukawa, Y. Ohmomo, A. Yokoyama, K. Okada, O. Yoshida, and S. Nishi, “Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against a-fetoprotein,” J. Nucl. Med. 26, 750-755 (1985).
103. S. Matzku, H. Kirchgessner, W. G. Dippold, and J. Bruggen, “Immu-noreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule,” Eur. J. Nucl. Med. 11, 260-264 (1985).
104. R. Muraro, M. Kuroki, D. Wunderlich, D. J. Poole, D. Colcher, A. Thor, J. W. Greiner, J. F. Simpson, A. Molinolo, P. Noguchi, and J. Schlom, “Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen,” Cancer Res. 48, 4588-4596 (1988).
105. D. Colcher, M. F. Minelli, M. Roselli, R. Muraro, D. Simpson-Milenic, and J. Schlom, “Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies,” Cancer Res. 48, 4597-4603 (1988).
106. J. Schlom, D. Eggensperger, D. Colcher, A. Molinolo, D. Houchens, L.S. Miller, G. Hinkle, and K. Siler, “Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates,” Cancer Res. 52, 1067-1072 (1992).
107. S. M. Andrew, R. W. Johnstone, S. M. Russell, I. F. C. McKenzie, and G. A. Pietersz, “Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice,” Cancer Res. 50, 4423-4428 (1990).
108. D. R. McCready, C. M. Balch, I. J. Fidler, and J. L. Murray, “Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo,” J. Natl. Cancer Inst. 81 682–687 (1989).
109. V. J. Philben, J. G. Jakowatz, B. G. Beatty, W. G. Vlahos, R. J. Paxton, L. E. Williams, J. E. Shively, and J. D. Beatty, “The effect of tumor CEA content and tumor size on tissue uptake of indium Ill-labeled anti-CEA monoclonal antibody,” Cancer 57, 571–576 (1986).
110. R. D. Blumenthal, R. M. Sharkey, R. Kashi, and D. M. Goldenberg, “Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model,” Int. J. Cancer 44, 292–300 (1989).
111. R. D. Blumenthal, R. M. Sharkey, R. Kashi, A. M. Natale, and D. M. Goldenberg, “Influence of animal host and tumor implantation site on radioantibody uptake in the GW-39 human colonic cancer xenograft,” Int. J. Cancer 44, 1041–1047 (1989).
112. T. R. Shockley, K. Lin, C. Sung, J. A. Nagy, R. G. Tompkins, R. L. Dedrick, H. F. Dvorak, and M. L. Yarmush, “A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels,” Cancer Res. 52, 357–366 (1992).
113. G. Rowlinson, F. Balkwill, D. Snook, G. Hooker, and A. A. Epenetos, “Enhancement by γ-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen,” Cancer Res. 46, 6413–6417 (1986).
114. F. Guadagni, J. Schlom, S. Pothen, S. Pestka, and J. W. Greiner, “Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon,” Cancer Immunol. Immu-nother. 26, 222–230 (1988).
115. M. Matsui, S. Yoshimura, T. Nakanishi, and S. Ferrone, “Effect of tumor size on the enhancement by /-interferon of the localization of radiolabeled F(ab‘)2fragments of anti-intercellular adhesion molecule-1 monoclonal antibodies in human colon carcinoma cells grafted in nude mice,” Cancer Res. 52, 1309–1313 (1992).
116. M. G. Rosenblum, L. M. Lamki, J. L. Murray, D. J. Carlo, and J. U. Gutterman, “Interferon-induced changes in pharmacokinetics and tumor uptake of 111 In-labeled antimelanoma antibody 96.5 in melanoma patients,” J. Natl. Cancer Inst. 80 160–165 (1988).
117. R. K. Jain and L. T. Baxter, “Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure,” Cancer Res. 48, 7022-7032 (1988).
118. K. Fujimori, D. G. Covell, J. E. Fletcher, and J. N. Weinstein, “Modeling analysis of the global and microscopic distribution of immuno-globulin G, F(ab’)2. and Fab in tumors,” Cancer Res. 49, 5656-5663(1989).
119. R. K. Jain, “Vascular and interstitial barriers to delivery of therapeutic agents in tumon,”; Cancer Metastasis Rev. 9, 253-266 (1990).
120. R. K. Jain, “Haemodynamic and transport barriers to the treatment of solid tumours,”; Int. J. Radiat. Biol. 60, 85-100 (1991).
121. M. Andrew, J. G. Teh, R. W. Johnstone, S. M. Russell, R. H. Whitehead, I. F. C. McKenzie, and G. A. Pietersz, “Tumor localization by combinations of monoclonal antibodies in a new human colon arcinoma cell line (LIM1899),” Cancer Res. 50, 5225-5230 (1990).
122. R. D. Blumenthal, R. Kashi, R. Stephens, R. M. Sharkey, and D. M. Goldenberg, “Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p,”; Cancer Immunol. Immunother. 32, 303-310 (1991).
123. H. Sands, P. L. Jones, S. A. Shah, D. Palme, R. L. Vessella, and B. M. Gallagher, “Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts,”; Cancer Res. 48, 88-193 (1988).
124. R. D. Blumenthal, R. M. Sharkey, R. Kashi, and D. M. Goldenberg, “Suppression of tumor vascular activity by radioantibody therapy: Im-plications for multiple cycle treatments,”; Selective Cancer Therapeu-tics 7, 9-16 (1991).
125. D. A. Cope, M. W. Dewhirst, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky, “Enhanced delivery of a monoclonal antibody F(ab’)2 fragment to subcutaneous human glioma xenografts using local hyperther-mia,”; Cancer Res. 50, 1803-1809 (1990).